CLL Combos: And the Winner Is... Medscape Dr. Cheson: For years we have been arguing about use of fludarabine-cyclophosphamide (FC), fludarabine-rituximab (FR), fludarabine-cyclophasphamide-rituximab (FCR), or bendamustine-rituximab (BR). There have been different factions on both sides of ... |
